Acorda Therapeutics to Host Analyst and Investor Reception

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc.® (Nasdaq: ACOR) today announced that Dr. Lauren Krupp, Professor of Neurology at Stony Brook University, will present data from Acorda's Phase 3 clinical trial of Fampridine-SR in multiple sclerosis at their analyst and investor reception on May 2, 2007. This reception will follow a presentation of this data at the American Academy of Neurology (AAN) annual meeting.